# Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

> **NCT03945253** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 6 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ASP8374

## Key facts

- **NCT ID:** NCT03945253
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-05
- **Primary completion:** 2020-06-12
- **Final completion:** 2020-06-12
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945253, "Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03945253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*